← Volver a la portada
Asia · Mercados regionales · Mint

After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally?

Publicado por Mint · India hace 5 h
After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally?(AI generated image)
After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally?(AI generated image) · Mint

Resumen detallado

Sellas shares climbed after its Phase 3 trial of GPS showed a significant survival benefit for patients with acute myeloid leukemia and no new safety concerns. The company plans to discuss an accelerated filing strategy with the FDA and aims to submit an application in 2027.

Shares of US-based biotechnology company Sellas Life Sciences extended their spectacular rally on Wednesday, November 18, rising another 5% after soaring nearly 156% in the previous session.

The stock has come under investors' radar following a major breakthrough in a late-stage clinical trial of its experimental cancer vaccine, which demonstrated a significant improvement in survival outcomes among patients with an aggressive form of blood cancer.

The sharp rally came after the company announced positive results from its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an investigational immunotherapeutic cancer vaccine designed to treat acute myeloid leukaemia (AML).

The results marked a significant milestone for the company, with the trial meeting its primary endpoint of overall survival. Sellas said the treatment reduced the risk of death by 41% compared with the best available treatment, with a hazard ratio of 0.59 and a statistically significant p-value of 0.035, as per the company's press release.

The company said that the 126-patient study showed that patients receiving GPS achieved median overall survival of 24 months, compared with 14.7 months among those receiving the best available treatment.

Acute Myeloid Leukemia (AML) is an aggressive cancer affecting the blood and bone marrow. According to the company, the vaccine works by training the body's immune system to identify and attack residual leukaemia cells carrying the WT1 protein.

The treatment was also generally well tolerated, with no new safety concerns identified and most treatment-related adverse events being mild to moderate.

The positive clinical findings have raised expectations around the vaccine's commercial potential and the company's regulatory roadmap. Sellas said it plans to meet with the US Food and Drug Administration (FDA) to discuss an accelerated filing strategy while advancing preparations for a Biologics License Application (BLA), targeting submission in the first half of…

The…

Inicio del artículo, extracto de Mint. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Mint Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.livemint.com)

También te puede interesar